Form 4: Insider Buys Shares in Intensity Therapeutics

John M. Wesolowski, an officer at Intensity Therapeutics, Inc., acquired shares through the company's Employee Stock Purchase Plan.

Summary

• John M. Wesolowski, an officer and Principal Accounting Officer of Intensity Therapeutics, Inc., acquired 3,688 shares of common stock.
• The acquisition occurred on June 30, 2026, under the company's Amended and Restated 2024 Employee Stock Purchase Plan (ESPP).
• The purchase price was 85% of the closing price of the Issuer's common stock on June 30, 2026, which amounted to $3.485 per share.
• Following this transaction, Wesolowski beneficially owns 7,102 shares of common stock directly.
• The filing also notes a 1-for-25 reverse stock split effectuated by the Issuer on February 18, 2026, which adjusted the number of shares held and outstanding equity awards.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine insider acquisition through an established employee stock purchase plan rather than a significant strategic event or a change in the company's financial performance.

Positives

• Insider participation in the ESPP indicates confidence in the company's stock.
• The acquisition was made at a discount (85% of closing price), suggesting a favorable purchase for the reporting person.
• The transaction is reported as exempt under Rule 16b-3(c) and Rule 16b-3(d), indicating compliance with regulatory provisions for insider transactions.

Negatives

• The filing does not contain any negative financial results or operational setbacks.

Risks

• The filing does not explicitly mention any current issues or potential future challenges.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Management Comments

• The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's Amended and Restated 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).
• In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2026.
• On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split.

Industry Context

StockSavvy.ai notes that insider purchases, especially through employee stock purchase plans, can signal management's belief in the company's future prospects, though this specific filing is a routine disclosure of an officer's participation in a pre-established plan.

Related Party Transactions

• Acquisition of common stock by John M. Wesolowski, an officer of Intensity Therapeutics, Inc., through the company's Employee Stock Purchase Plan.

Stakeholder Impact

• Shareholders: The transaction may be viewed positively as an insider's investment in the company, but it is a standard ESPP purchase and not indicative of a major shift.
• Employees: The ESPP provides an opportunity for employees, including management, to acquire company stock at a discount.
• Management: John M. Wesolowski increased his direct beneficial ownership of the company's stock.

Next Steps

• Continue to monitor future SEC filings for any further transactions by reporting persons or significant company announcements.

Key Dates

Keywords

Form 4, Insider Transaction, Intensity Therapeutics, INTS, Employee Stock Purchase Plan, ESPP, Common Stock, Beneficial Ownership, Reverse Stock Split, SEC Filing